gastric cancer with peritoneal metastasis
Conditions
Interventions
PTX is administered intraperitoneally at 20 mg/m2 on days 1,8 and 22. S-1 is administered at 80 mg/m2/day for 21 consecutive days, followed by 14 days rest. Cisplatin is administered at 60 mg/m2 o
Sponsors
Nagoya University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Histologically proven unresectable or recurrent gastric adenocarcinoma; peritoneal metastasis; age more than 20 years; Eastern Cooperative Oncology Group performance status 0-1; adequate bone marrow function (leukocyte count 3,300-12,000/mm3, hemoglobin >8.0 g/dl, platelet count >100,000/mm3); adequate liver function (total serum bilirubin <2.0 mg/dl, serum transaminases <100/UI); Ccr>=60mL/min; and an expected survival period of more than 3 months.
Exclusion criteria
Exclusion criteria: Metastasis to distant organ sites (such as the liver, lungs or bone), other active concomitant malignancies, or other severe medical conditions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1-year overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| response rate negative conversion rate on peritoneal cytology safety | — |
Countries
Japan
Contacts
Public ContactDaisuke Kobayashi
Nagoya University Department of Gastroenterological Surgery
Outcome results
None listed